Zhang Lei, Li Guangping, Zhang Hongxin, Liu Huaqun, Li Songlin, Wang Yanan, Qi Huisheng
Department of Respiration, Tangshan Workers' Hospital, Tangshan, 063000, People's Republic of China.
Department of Clinical Laboratory, Tangshan Workers' Hospital, Tangshan, 063000, People's Republic of China.
Cancer Manag Res. 2022 Jun 7;14:1903-1910. doi: 10.2147/CMAR.S352217. eCollection 2022.
Lung cancer (LC) is the leading type of cancer worldwide, yet it's challenging to detect early LC. Therefore, it is valuable to explore diagnostic biomarker that can distinguish malignant pulmonary lesions from benign diseases. The potential role of plate factor-4 variant (CXCL4L1) will be investigated in detecting early LC.
A consecutive of 174 patients with single pulmonary nodule and 50 healthy controls were enrolled. Serum CXCL4L1 expression level was evaluated using ELISA. Survival curves were generated to analyze survival outcomes. Receiver operating characteristic curves were used to calculate diagnostic accuracy.
Serum CXCL4L1 was downregulated in patients with LC when compared with those with lung benign lesions (LBL) or healthy controls. Meanwhile, lower serum CXCL4L1 expression was associated with advanced TNM stage and lymph node metastasis. Furthermore, a low expression of CXCL4L1 resulted in worse survival outcomes in LC patients. Serum CXCL4L1 expression obtained an area under curve (AUC) of 0.81 (95% CI: 0.74-0.88), a sensitivity of 70.6%, and a specificity of 85.8% for discriminating patients with LC form patients with LBL. In addition, serum CXCL4L1 expression achieved an AUC of 0.82 (95% CI, 0.74-0.90), a sensitivity of 72.0%, and a specificity of 85.9% for distinguishing patients with LC form healthy controls.
This study suggests that CXCL4L1 may prove to be a potential non-invasive diagnostic and prognostic biomarker for early LC patients.
肺癌是全球主要的癌症类型，但早期肺癌的检测具有挑战性。因此，探索能够区分恶性肺部病变与良性疾病的诊断生物标志物具有重要价值。本研究将探讨血小板因子-4变体（CXCL4L1）在早期肺癌检测中的潜在作用。
纳入174例单发肺结节患者和50例健康对照。采用酶联免疫吸附测定法评估血清CXCL4L1表达水平。绘制生存曲线分析生存结果。采用受试者工作特征曲线计算诊断准确性。
与肺良性病变（LBL）患者或健康对照相比，肺癌患者血清CXCL4L1表达下调。同时，血清CXCL4L1低表达与晚期TNM分期及淋巴结转移相关。此外，CXCL4L1低表达导致肺癌患者生存结果较差。血清CXCL4L1表达对区分肺癌患者与LBL患者的曲线下面积（AUC）为0.81（95%CI：0.74-0.88），灵敏度为70.6%，特异度为85.8%。此外，血清CXCL4L1表达对区分肺癌患者与健康对照的AUC为0.82（95%CI，0.74-0.90），灵敏度为72.0%，特异度为85.9%。
本研究表明，CXCL4L1可能是早期肺癌患者潜在的非侵入性诊断和预后生物标志物。
